Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Cancer Drug May Cause Women to Grow New Eggs, Study Suggests

By University of Edinburgh | December 7, 2016

Follicles in ovarian tissue from (i) a 22-year-old treated with ABVD chemotherapy, (ii) from an untreated 8-year-old; (iii) a healthy 23-year-old; and following OEPA COPDAC chemotherapy treatment (iv). (Credit: University of Edinburgh)

Women treated with a common chemotherapy drug combination have more young eggs in their ovaries afterwards, research has found.

A small study indicates that a therapy commonly used to target Hodgkin’s lymphoma appears to increase the number of non-growing eggs in women’s ovaries.

Researchers say it is too soon to link the outcome to fertility, but believe more research is needed to better understand the findings and their implications.

Scientists from the University of Edinburgh analyzed samples of ovary tissue donated by 14 women who had undergone chemotherapy, and from 12 healthy women.

They found that the ovaries from eight of the cancer patients, who had been treated with a drug combination known as ABVD, had a much greater incidence of immature, or non-growing, eggs compared with tissue from women who had received a different chemotherapy, or from healthy women of a similar age.

The ovary tissue was seen to be in healthy condition, appearing similar to tissue from young women’s ovaries.

If further research can reveal the mechanism by which treatment with ABVD results in increased production of eggs, this would aid understanding of how women might be able to produce more eggs during their lifetime, which was until recently thought to be impossible.

Researchers had set out to better understand why treatment with ABVD is one of the few cancer drug combinations that does not impact on women’s fertility. 

Future studies will examine the separate impact of each of the four drugs that combine to make ABVD — known as adriamycin, bleomycin, vinblastine and dacarbazine — to better understand the biological mechanisms involved.

The study, published in Human Reproduction, was supported by the Medical Research Council.

Lead researcher Professor Evelyn Telfer of the University of Edinburgh’s School of Biological Sciences, said: “This study involves only a few patients, but its findings were consistent and its outcome may be significant and far-reaching. We need to know more about how this drug combination acts on the ovaries, and the implications of this.”

(Source: EurekAlert!)


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE